3rd Inner Ear Disorders Therapeutics Summit

The development of next-generation drug-based approaches to treat inner ear disorders is gaining momentum, with multiple INDs approved in the last six months and big pharma making plays to acquire innovative biotechs working on hearing loss.

However, in a space that has also had to battle with multiple clinical failures, there's a genuine need for the industry to unite and overcome the specific obstacles that are currently acting as a barrier to late-stage clinical trials and through to approval.

That's why the 3rd Inner Ear Disorders Therapeutics Summit is back this summer, bringing together the community to collectively accelerate development of drug-based approaches, sharing case studies and data-driven insights into optimizing preclinical programs and designing translational studies to ultimately validate clinically relevant targets.

This meeting will leverage the latest biotech and academic innovation alongside big pharma experience to address the technical and strategic challenges in delivering a safe and effective therapy to the inner ear.

URLs:
Website: https://go.evvnt.com/1718893-0?pid=10018
Tickets: https://go.evvnt.com/1718893-1?pid=10018
Brochure: https://go.evvnt.com/1718893-3?pid=10018

Prices:
Drug Developer Pricing - Conference + 2 Workshops: USD 4297.00,
Drug Developer Pricing - Conference + 1 Workshop: USD 3648.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Solution Provider Pricing - Conference + 2 Workshops: USD 5297.00,
Solution Provider Pricing - Conference + 1 Workshop: USD 4548.00,
Solution Provider Pricing - Conference Only: USD 3799.00,
Start-up and Academic Pricing - Conference + 2 Workshops: USD 3697.00,
Start-up and Academic Pricing - Conference + 1 Workshop: USD 3148.00,
Start-up and Academic Pricing - Conference Only: USD 2599.00

Speakers: Barbara Kelley, Executive Director and CEO, Hearing Loss Association of Pennsylvania, Benjamin Chen, Partner, Panacea Ventures, Catherine Perrodin, Translational Research Manager, RNID, Chieri Hayashi, Medical Director, Astellas Pharma, Jian Zuo, Co-Founder and CEO, Ting Therapeutics, Jonas Dyhrfjeld-Johnsen, Chief Development Officer, Acousia Therapeutics, David Raible, Co-founder, Oricular Therapeutics Professor, University of Washington, Erdem Yildiz, MD Researcher, Medical University of Vienna, Hugo Peris, Chief Executive Officer, Spiral Therapeutics, Kevin Franck, Strategic Marketing and New Product Planning, Frequency Therapeutics former Chief Audiology, Harvard Medical School, Laurent Desire, Head of Preclinical Development, Sensorion, Lisa Hunter Scientific, Director of Research, Division of Audiology, Cincinnati Children's Hospital Medical Center, Manny Simons, Chief Executive Officer, Akouos, Reimar Schlingensiepen, CEO, AudioCure Pharma, Steven Rauch, Professor of Otolaryngology - Head and Neck Surgery, Vice Chair for Clinical Research, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Vincent Groppi, Co-founder and Chief Executive Office, Oricula Therapeutics, William Slattery, Chief Executive Officer, O-Ray Pharma, Yunlong Huang, Senior Scientist, Ting Therapeutics